The Central Core Media Laboratory will be responsible for the production of stringent quality-controlled sterile tissue culture and bacteriological media and buffers necessary for in vitro research by all laboratory researchers at the University of Texas M.D. Anderson Cancer Center. Numerous pathogen-free chemically defined solutions will be available for immediate delivery at lower cost than commercial products. The Central Core Media Laboratory will be located in the new Bertner Clinical Research Building, in T5.3964 and consist of approximately 1,300 square feet of laboratory space and 200 square feet of cold-room space. The high trained staff will offer personalized service tailored to each researcher's needs. Two research technicians will prepare solutions and perform quality-control checks. A facility manager will be responsible for performance evaluations, accounting procedures, and general supervision of the laboratory. The facility manager will report regularly to the project investigator. An oversight committee will meet quarterly to assist with the commission of the facility and in determining policy changes. This centralized resource will alleviate the duplication of personnel and valuable laboratory space by concentrating these services into one dedicated location.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-24
Application #
6101827
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Korch, Christopher; Hall, Erin M; Dirks, Wilhelm G et al. (2018) Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. Int J Cancer 142:561-572
Lee, Jong-Ho; Liu, Rui; Li, Jing et al. (2018) EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol Cell 70:197-210.e7
Brown, Justin C; Troxel, Andrea B; Ky, Bonnie et al. (2018) Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial. Clin Colorectal Cancer 17:32-40
Zhang, Hong; Wang, Yirong; Li, Jun et al. (2018) Biosynthetic energy cost for amino acids decreases in cancer evolution. Nat Commun 9:4124
Vilar-Compte, Diana; Shah, Dimpy P; Vanichanan, Jakapat et al. (2018) Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. J Med Virol 90:50-60
Bambhroliya, Arvind; Van Wyhe, Renae D; Kumar, Swaminathan et al. (2018) Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer. PLoS One 13:e0192689
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Jain, N; Zhu, H; Khashab, T et al. (2018) Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia 32:663-674
Parker, Patricia A; Peterson, Susan K; Shen, Yu et al. (2018) Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. J Clin Oncol 36:2630-2638
Fathi, Amir T; Erba, Harry P; Lancet, Jeffrey E et al. (2018) A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132:1125-1133

Showing the most recent 10 out of 12418 publications